Can treating my allergies reduce asthma attacks?

📋 Medically reviewed by Dr. Neeta Ogden, MD, FACAAI · Sources verified against peer-reviewed literature

The evidence is mixed — genuinely mixed, not just hedging. The largest real-world dataset comes from the REACT study: Fritzsching et al. 2022 analyzed 46,024 immunotherapy-treated patients matched with controls using German health claims data over 9 years. They found AIT was associated with significant reductions in asthma medication prescriptions compared to controls, with SCIT and SLIT tablets showing comparable effectiveness. This is compelling but observational — not a controlled trial. In contrast, the Cochrane review (Fortescue et al. 2020) pooled 66 randomized controlled trials with 7,944 patients and rated the evidence for SLIT's effect on asthma exacerbations as "very low certainty." Only 2 trials (108 patients) reported on the critical outcome of emergency department visits or hospitalizations. The Cochrane authors concluded: "the evidence for important outcomes such as exacerbations and quality of life remains too limited to draw clinically useful conclusions."

Despite the cautious Cochrane conclusion, specific areas of the evidence base are stronger. The following table summarizes the key studies by evidence type.

The evidence for immunotherapy is stronger for preventing asthma in allergic children than for treating established asthma in adults. The PAT study (Moller et al. 2002, Jacobsen et al. 2007) demonstrated that 3 years of pollen immunotherapy halved the rate of asthma development in children with allergic rhinitis — from 45% in controls to 25% in treated children — and the protective effect persisted at least 7 years after treatment ended. Marogna et al. 2008 found even more dramatic results with SLIT: asthma developed in only 1.5% of treated children versus 30% of controls, and new allergen sensitizations occurred in 3.1% versus 34.8%. For adults with established moderate-to-severe asthma, the picture is less clear. The Cochrane review's (Fortescue et al. 2020) cautious conclusion reflects the difficulty of demonstrating SLIT benefit when patients are already on effective controller medications. The Odactra asthma trial by Virchow et al. 2016 addressed this cleverly — measuring exacerbations during the period when inhaled corticosteroids were being reduced — and found a 31-34% reduction in risk (HR 0.69).

Immunotherapy targets the allergic immune pathway specifically. If your asthma is not driven by allergen sensitization, immunotherapy will not help. Approximately 40% of adult asthma is non-allergic — triggered by exercise, cold air, occupational exposures, aspirin/NSAID sensitivity, or stress. Get tested before investing in a 3-5 year treatment course. Additionally, if your asthma is already severe (step 5 treatment with high-dose ICS plus LABA plus oral corticosteroids or biologics), starting immunotherapy is contraindicated until asthma is better controlled. For patients with mild allergic asthma well-controlled on low-dose fluticasone ($18/month generic), the benefit of adding immunotherapy may not justify the cost and time commitment. Immunotherapy makes the most sense for moderate allergic asthma that requires multiple controller medications and still causes breakthrough symptoms.